ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara

robot
Abstract generation in progress

Faruqi & Faruqi, LLP reminds investors of the May 22, 2026 deadline to seek lead plaintiff status in a federal securities class action against Atara Biotherapeutics (ATRA). The lawsuit alleges that Atara and its executives made misleading statements regarding tabelecleucel’s regulatory prospects, particularly concerning manufacturing issues and deficiencies in the ALLELE study, which ultimately led to a Complete Response Letter from the FDA and a significant drop in stock price. Investors who purchased Atara securities between May 20, 2024, and January 9, 2026, and suffered losses are encouraged to contact the firm.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin